PT - JOURNAL ARTICLE AU - Lei, Qing AU - Yu, Cai-zheng AU - Li, Yang AU - Hou, Hong-yan AU - Xu, Zhao-wei AU - Yao, Zong-jie AU - Zhang, Yan-di AU - Lai, Dan-yun AU - Ndzouboukou, Jo-Lewis Banga AU - Zhang, Bo AU - Chen, Hong AU - Ouyang, Zhu-qing AU - Xue, Jun-biao AU - Lin, Xiao-song AU - Zheng, Yun-xiao AU - Wang, Xue-ning AU - Jiang, He-wei AU - Zhang, Hai-nan AU - Qi, Huan AU - Guo, Shu-juan AU - He, Mei-an AU - Sun, Zi-yong AU - Wang, Feng AU - Tao, Sheng-ce AU - Fan, Xiong-lin TI - SARS-CoV-2 antibody signatures for predicting the outcome of COVID-19 AID - 10.1101/2020.11.10.20228890 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.10.20228890 4099 - http://medrxiv.org/content/early/2020/11/15/2020.11.10.20228890.short 4100 - http://medrxiv.org/content/early/2020/11/15/2020.11.10.20228890.full AB - The COIVD-19 global pandemic is far from ending. There is an urgent need to identify applicable biomarkers for predicting the outcome of COVID-19. Growing evidences have revealed that SARS-CoV-2 specific antibodies remain elevated with disease progression and severity in COIVD-19 patients. We assumed that antibodies may serve as biomarkers for predicting disease outcome. By taking advantage of a newly developed SARS-CoV-2 proteome microarray, we surveyed IgM/IgG responses against 20 SARS-CoV-2 proteins in 1,034 hospitalized COVID-19 patients on admission, who were followed till 66 days. The microarray results were correlated with clinical information, laboratory test results and patient outcomes. Cox proportional hazards model was used to explore the association between SARS-CoV-2 specific antibodies and COVID-19 mortality. We found that high level of IgM against ORF7b at the time of hospitalization is an independent predictor of patient survival (p trend = 0.002), while levels of IgG responses to 6 non-structural proteins and 1 accessory protein, i. e., NSP4, NSP7, NSP9, NSP10, RdRp (NSP12), NSP14, and ORF3b, possess significant predictive power for patient death, even after further adjustments for demographics, comorbidities, and common laboratory markers for disease severity (all with p trend < 0.05). Spline regression analysis indicated that the correlation between ORF7b IgM, NSP9 IgG, and NSP10 IgG and risk of COVID-19 mortality is linear (p = 0.0013, 0.0073 and 0.0003, respectively). Their AUCs for predictions, determined by computational cross-validations (validation1), were 0.74 (cut-off = 7.59), 0.66 (cut-off = 9.13), and 0.68 (cut-off = 6.29), respectively. Further validations were conducted in the second and third serial samples of these cases (validation2A, n = 633, validation2B, n = 382), with high accuracy of prediction for outcome. These findings have important implications for improving clinical management, and especially for developing medical interventions and vaccines.HighlightsIgM/IgG responses of 1,034 patients upon admission against 20 SARS-CoV-2 proteins were analyzed.High level of IgM against ORF7b at the time of hospitalization is an independent predictor of patient survival.IgG responses to NSP9 and NSP10 possess significant predictive power for patient death.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the National Mega-Projects of Science Research for the 13th Five-year Plan of China (No. 2018ZX10302302002-001), the Natural Science Foundation of China (No. 81971909), and the Fundamental Research Funds for the Central Universities (HUST COVID-19 Rapid Response Call No. 2020kfyXGYJ040). This work was partially supported by National Key Research and Development Program of China Grant (No. 2016YFA0500600), National Natural Science Foundation of China (No. 31970130, 31670831, 31370813 and 31501054).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethical Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (IRB ID:TJ-C20200128). Written informed consent was obtained from all participants enrolled in this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study are available from the corresponding author upon request.